CareDx reported validation data for AlloHeme, its cell‑free DNA sequencing assay for allogeneic hematopoietic cell transplant (HCT) surveillance, demonstrating 85% sensitivity and 92% specificity with a median 41‑day lead time for detecting relapse. The company plans to publish the ACROBAT study and prepare for a commercial launch next year. Investigators highlighted AlloHeme’s negative predictive value as a key clinical advantage versus standard bone marrow testing, emphasizing earlier intervention opportunities for relapse. CareDx will focus on regulatory readiness, clinician engagement and workflow integration ahead of market entry.